2 ms·
As someone who works in the industry, the article was a 30,000 ft view and didn’t do a good job of digging into the issue. Regardless, it looks like the drug d
by refurb 8y ago
As someone who works in the industry, the article was a 30,000 ft view and didn’t do a good job of digging into the issue.
Regardless, it looks like the drug does reduce pancreatitis attacks, but only by 50%. So it certainly doesn’t “cure” the patient.
The clinical trials were also quite small, so possibly the national payers said “$1M is reasonable if you do X, but you don’t have the data to convince me you can do X.”